“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.
Sam S. Chang, MD, MBA, discusses results from the phase 2/3 QUILT-3.032 trial showing the efficacy of the combination of BCG and the novel interleukin-15 superagonist N-803 in patients with BCG-unresponsive bladder cancer.
Chang is a professor in the Department of Urology, Patricia and Rodes Hart Professor of Urologic Surgery, and chief surgical officer and chief of the Division of Urologic Oncology at Vanderbilt Ingram Cancer Center.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
FDA fast tracks treatment for immune checkpoint inhibitor–resistant urothelial carcinoma
March 13th 2023“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.
2 Clarke Drive
Cranbury, NJ 08512